Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Annovis Bio. The associated price target remains the same with $8.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason McCarthy has given his Buy rating due to a combination of factors related to Annovis Bio’s ongoing clinical developments. The company is making significant progress in its Phase 3 study for Alzheimer’s disease, with all clinical sites activated and patient enrollment underway. This study aims to evaluate the efficacy of buntanetap, a promising treatment for early Alzheimer’s, with initial results expected in the second half of 2026.
Furthermore, recent biomarker data from a previous Phase 2/3 study showed positive outcomes, such as reduced neuroinflammation and improved neuroprotection, which are crucial in slowing Alzheimer’s progression. These findings suggest that buntanetap could potentially modify the disease course, enhancing its appeal as a therapeutic option. The combination of these clinical advancements and promising biomarker results underpins McCarthy’s optimistic outlook on Annovis Bio’s stock.
McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, OS Therapies Incorporated, and Neuphoria Therapeutics. According to TipRanks, McCarthy has an average return of -14.4% and a 33.20% success rate on recommended stocks.